Evonik stock trades near its 52-week high at EUR 21.07

Published on 10/08/2026 at 11:51 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Evonik stock costs EUR 21.07 on October 8, 2026 after EUR 20.93, plus 0.67 percent. Third-quarter results with full figures follow on November 3, 2026.

Isometrische 3D-Illustration der Spezialchemie-Wertschöpfungskette von Rohstoff bis globale Distribution — Evonik Industries DE000EVNK013 als isometrisches 3D-Diagramm der Spezialchemie-Wertschöpfungskette von Rohstoff bis Vertrieb, Illustration mit AI erstellt.

Evonik Industries (DE000EVNK013) was trading at EUR 21.07 at Lang & Schwarz on October 8, 2026 at 11:41 a.m. CEST, just 0.24 percent below its EUR 21.12 52-week high. The stock was up 0.67 percent from the Lang & Schwarz prior close of EUR 20.93. Evonik's next reporting date is November 3, 2026, according to the company's investor relations page.

Results arrive on November 3

The scheduled third-quarter report gives investors the next hard test of Evonik's earnings recovery. The company reported adjusted EBITDA of EUR 630.0 million in the second quarter of 2026, according to Yahoo Finance, an increase of 24.00 percent from the second quarter of 2025.

The comparison was supported by higher volumes and prices, with management assigning a 7.00 percent contribution to each factor. Adjusted EBITDA reached EUR 1.1 billion in the first half of 2026, leaving another EUR 1.0 billion needed in the second half to reach the midpoint of the upgraded outlook, the Yahoo Finance transcript reported.

Analyst target stays below price

Parmantier & Cie. assigned Evonik a Hold rating and a EUR 20.50 12-month price target in research dated October 6, 2026, according to TradingView. That target is EUR 0.57 below the Lang & Schwarz price, putting the analyst view below the latest German-market indication.

The contrast matters because the second-quarter improvement was not evenly distributed across the portfolio. The earnings call highlighted Advanced Technologies, methionine pricing and cost savings, while also pointing to normalization in selected businesses during the second half of 2026.

Evonik is also pursuing structural cost reductions. Management said the extended program targets 3,200 additional positions between 2027 and 2029, following reductions linked to the earlier program, according to Yahoo Finance.

Stock tests the yearly peak

At EUR 21.07, Evonik stock was 0.24 percent below the EUR 21.12 52-week high on October 8, 2026. The move leaves the November report as the next dated operating checkpoint, with the second-quarter adjusted EBITDA comparison providing the latest quantified benchmark.

The further course of trading is shown by the continuously updated real-time quote of Evonik stock.